We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our purpose is resolute and fueled by the opportunity to improve the lives of millions of women and men, many impacted by diseases during their most productive years of life.
Does Myfembree shrink fibroids?
Myfembree doesn't get rid of or cure uterine fibroids (growths on or in the uterus that aren't cancer). The medication is used to treat a common symptom of uterine fibroids: heavy periods. Taking Myfembree may help make your periods lighter.
Does Pfizer own Myovant?
Pfizer is paying Myovant up to $4.2 billion, including an upfront payment of $650 million and $200 million in potential regulatory milestones, and tiered sales milestones after hitting specific thresholds up to $2.5 billion in net sales for prostate cancer and also for the combined women's health indications.
Where is Myovant Sciences located?
Where we. call home. We have offices in Brisbane, California, and Basel, Switzerland, with employees from all over the world. Our office in Brisbane is in the heart of Silicon Valley, surrounded by top universities and institutions.
Where is Myovant located?
Myovant Sciences is headquartered in Brisbane, CA and has 2 office locations across 2 countries.
What does Myovant Sciences Ltd do?
Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders.
Should I buy Myovant Sciences stock?
Myovant Sciences - Hold Valuation metrics show that Myovant Sciences may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. Recent price changes and earnings estimate revisions indicate this stock lacks momentum and would be a lackluster choice for momentum investors.